FDA's Dapagliflozin Review To Focus On Hepatic Effects, Cancer Risks

The agency will ask its Endocrinologic and Metabolic Drugs Advisory Committee to weigh these "unexpected" safety findings despite a clean cardiovascular profile for Bristol-Myers Squibb/AstraZeneca's first-in-class diabetes drug.